DH hosted 12th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards (with photo)

     The Department of Health yesterday (August 16) hosted the 12th meeting of the International Advisory Board (IAB) on Hong Kong Chinese Materia Medica Standards (HKCMMS) via video conference to finalise the setting of reference standards for Chinese Materia Medica (CMM) commonly used in Hong Kong.
     The IAB was established in early 2002 to give advice on the principles, methodologies and analytical methods for the development of the HKCMMS. It also decides the contents of the HKCMMS and determines target herbs. The meeting yesterday brought together around 20 renowned experts in the field of herbal medicines from local, the Mainland and overseas, including, Australia, Austria, Canada, Germany, Japan, Thailand, the United Kingdom and the United States. At the meeting, the IAB reviewed and concluded the research work for 16 CMM for the HKCMMS project. 
     Addressing the opening session of the meeting, the Director of Health, Dr Ronald Lam, said, "We have already published 10 volumes of the HKCMMS, with reference standards for a total of 330 CMM. The HKCMMS have become well-recognised reference standards in the field of Chinese medicines' testing and certification. Such achievements could not have been actualised without the ardent support from the IAB and concerted efforts of our research institutions."
     Dr Lam further remarked that the project of setting standards for CMM relies heavily on the participation of the scientific community, and the Government is most grateful to the four research partners who participated in this phase of the HKCMMS project, namely the Chinese University of Hong Kong, the University of Hong Kong, the National Institutes for Food and Drug Control of the People's Republic of China and Taiwan's China Medical University for rallying behind the project and making efforts to meet various challenges in setting standards. Moreover, the Government Laboratory is continuing to conduct inter-laboratory verification studies, which is important in gaining scientific rigour and credibility for the project.
     "Hong Kong, China is an important bridge and window to connect with the world. The Government will continue to support the inheritance, innovation and development of Chinese medicine, with the aim to promote modernisation and internationalisation of Chinese medicine. We will push forward innovation, talent nurturing and technology transfers, in order to allow 'modernised Chinese medicines' to take root in the Guangdong-Hong Kong-Macao Greater Bay Area, and to promote Chinese medicine to 'go global'," Dr Lam added.
     Previous publications of HKCMMS can be accessed at www.cmro.gov.hk/html/eng/useful_information/hkcmms/volumes.html.

Ends/Wednesday, August 17, 2022
Issued at HKT 12:00